Insulet Corp (PODD)
170.22
-1.72
(-1.00%)
USD |
NASDAQ |
May 01, 16:00
167.95
-2.27
(-1.33%)
Pre-Market: 08:08
Insulet SG&A Expense (Quarterly): 212.80M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 212.80M |
September 30, 2023 | 180.70M |
June 30, 2023 | 178.70M |
March 31, 2023 | 162.70M |
December 31, 2022 | 144.30M |
September 30, 2022 | 140.40M |
June 30, 2022 | 174.40M |
March 31, 2022 | 128.70M |
December 31, 2021 | 121.70M |
September 30, 2021 | 117.50M |
June 30, 2021 | 116.30M |
March 31, 2021 | 110.50M |
December 31, 2020 | 130.10M |
September 30, 2020 | 89.20M |
June 30, 2020 | 80.80M |
March 31, 2020 | 83.90M |
December 31, 2019 | 80.50M |
September 30, 2019 | 74.80M |
June 30, 2019 | 75.80M |
March 31, 2019 | 66.90M |
December 31, 2018 | 60.74M |
September 30, 2018 | 72.77M |
June 30, 2018 | 58.95M |
March 31, 2018 | 55.55M |
December 31, 2017 | 60.29M |
Date | Value |
---|---|
September 30, 2017 | 51.44M |
June 30, 2017 | 49.97M |
March 31, 2017 | 47.21M |
December 31, 2016 | 49.04M |
September 30, 2016 | 39.49M |
June 30, 2016 | 38.79M |
March 31, 2016 | 38.76M |
December 31, 2015 | 41.71M |
September 30, 2015 | 36.33M |
June 30, 2015 | 32.50M |
March 31, 2015 | 28.25M |
December 31, 2014 | 12.06M |
September 30, 2014 | 33.76M |
June 30, 2014 | 34.37M |
March 31, 2014 | 27.92M |
December 31, 2013 | 26.39M |
September 30, 2013 | 38.94M |
June 30, 2013 | 27.48M |
March 31, 2013 | 26.96M |
December 31, 2012 | 25.56M |
September 30, 2012 | 26.30M |
June 30, 2012 | 26.33M |
March 31, 2012 | 25.76M |
December 31, 2011 | 24.79M |
September 30, 2011 | 23.69M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
74.80M
Minimum
Sep 2019
212.80M
Maximum
Dec 2023
126.52M
Average
121.70M
Median
Dec 2021
SG&A Expense (Quarterly) Benchmarks
Abbott Laboratories | 2.959B |
Stryker Corp | 1.84B |
Becton Dickinson & Co | 1.213B |
Haemonetics Corp | 111.71M |
Tandem Diabetes Care Inc | 85.75M |